Moderator I need help locating article in library PM

Discussion in 'Fibromyalgia Main Forum' started by PaulMark, Jul 5, 2003.

  1. PaulMark

    PaulMark New Member

    dear moderator i'm not very good at locating this can you help me located this artice to printout for unbeliving family members who don't beleive protocols or dangers of mercury toxicity please thansk paul mark

    HealthWatch by Bernie Windham called "Chronic Fatigue Syndrome, Fibromyalgia, Scleroderma, and Lupus: The Mercury Connection": www.immunesupport.com/library/showarticle.cfm/id/3305
  2. elaine_p

    elaine_p New Member

    Paul, I just did a search in the libary for: Bernie Windham.

    Chronic Fatigue Syndrome, Fibromyalgia, Scleroderma, and Lupus: The Mercury Connection
    by Bernie Windham
    ImmuneSupport.com

    01-30-2002

    Chronic Fatigue Syndrome(CFS) is characterized by fatigue, neurologic symptoms including headaches, brain fog, mood disorders, and motor dysfunction. Spect scans of those with CFS have found that the majority have over 5 times more areas of regional brain damage and reduced blood flow in the cerebral cortex area of the brain(471) than controls.

    The majority studied were also found to have increased Th2 inflammatory cytokine activity and a blunted DHEA response curve to I.V. ATCH indicative of hypothalamic/adrenal deficiency such as relative glucocorticoid deficiency(472). CFS and fibromyalgia patients have also been found to commonly have abnormal enzymatic processes that affect the sodium-potassium ATPase energy channels(473), which appears to be a major factor in the condition and for which mercury is a known cause(43,288).

    This also has been found to result in inflammatory processes that cause muscle tissue damage and result in higher levels of urinary excretion of creatine, choline, and glycine in CFS, and higher levels of excretion of choline, taurine, citrate, and trimethyl amine oxide in FM(474).

    Supplementation of creatine has been found to result in improved muscle mitochondrial function in such patients(502). A Swedish study found that in one county, 11.6% of women over 35 surveyed had symptoms of fibromyalgia, while 5.5% of men reported such symptoms(368).

    The main factors determining whether chronic conditions are induced by metals appear to be exposure and genetic susceptibility, which determines an individual's immune sensitivity and ability to detoxify metals(405). Very low levels of exposure have been found to seriously affect relatively large groups of individuals who are immune sensitive to toxic metals, or have an inability to detoxify metals due to such as deficient sulfoxidation or metallothionein function, or other inhibited enzymatic processes related to detoxification or excretion of metals.

    For those with chronic conditions, fatigue - regardless of the underlying disease, is primarily associated with hypersensitivity to inorganic and organic mercury, nickel, and gold(369,382).

    Mercury (especially mercury vapor) rapidly crosses the blood brain barrier and is stored preferentially in the pituitary gland(14,327), hypothalamus(348c), thyroid gland(99), adrenal gland, and occipital cortex in direct proportion to the number and extent of amalgam surfaces(14,19,20,25,34,38,85,99,273,274,287,348,366). Thus, mercury has a greater effect on the functions of these areas. The range in one study was 2.4 to 28.7 ppb(85), and one study found on average that 77% of the mercury in the occipital cortex was inorganic(363).

    A direct mechanism involving mercury's inhibition of cellular enzymatic processes by binding with the hydroxyl radical(SH) in amino acids, appears to be a major part of the connection to allergic/immune reactive conditions such as lupus (330,331,468) and schleraderma(468), as well as CFS and FM that are also related to inflammatory cytokine processes and autoimmunity(181,314,405,500,).

    One study found that insertion of amalgam fillings or nickel dental materials causes a suppression of the number of T-lymphocytes(270), and impairs the T-4/T-8 ratio. Low T4/T8 ratio has been found to be a factor in lupus, anemia, MS, eczema, inflammatory bowel disease, and glomerulonephritis. Mercury induced autoimmunity in animals and humans has been found to be associated with mercury's expression of major histocompatibility complex(MHC) class II genes(314,181,226,425c). Both mercuric and methyl mercury chlorides caused dose dependent reduction in immune B-cell production.(316) B-cell expression of IgE receptors were significantly reduced(316,165), with a rapid and sustained elevation in intracellular levels of calcium induced(316,333).

    Mercury and other toxic metals also form inorganic compounds with OH, NH2, CL, in addition to the SH radical and thus inhibits many cellular enzyme processes, coenzymes, hormones, and blood cells(405,500). Mercury has been found to impair conversion of thyroid T4 hormone to the active T3 form as well as causing autoimmune thyroiditis common to such patients(369,382).

    In general, immune activation from toxic metals such as mercury resulting in cytokine release and abnormalities of the hypothalamus-pituitary-adrenal(HPA) axis, can cause changes in the brain, hypocortisolism, fatigue, and severe psychological symptoms (348,369,375,379-382,385,405,118), such as profound fatigue, musculoskeletal pain, sleep disturbances, gastrointestinal and neurological problems as are seen in CFS, fibromyalgia, and autoimmune thyroiditis. Such hypersensitivity has been found most common in those with genetic predisposition to heavy metal sensitivity(60,313,342,369,405), such as found more frequently in patients with human lymphocyte antigens(HLA-DRA) (381-383). A significant portion of the population appear to fall in this category.

    Mercury exposure through dental fillings appears to be a major factor in Chronic Fatigue Syndrome(CFS) through its effects on ATP and the immune system(lymphocyte reactivity, neutraphil activity, effects on T-cells and B-cells), as well as its promotion of growth of candida albicans in the body, and the methylation of inorganic mercury by candida and intestinal bacteria, to the extremely toxic methyl mercury form, which like mercury vapor crosses the blood-brain barrier, and also damages and weakens the immune system (222,225,226,234,235, 265, 293,60,313,314,342,369,404).

    Mercury vapor or inorganic mercury have been shown in animal studies to induce autoimmune reactions and disease through effects on immune system T-cells(226,268,269,270,314). Chronic immune activation is common in CFS, with an increase in activated CD8+ cytotoxic T-cells, and decreased NK (Natural Killer) cells(518). CFS patients usually improve, and immune reactivity is reduced, when amalgam fillings are replaced(342,383,405).

    Mercury lymphocyte reactivity, effects on glutamate in the CNS (Central Nervous System), and mercury induced hypothyroidism, induce CFS-type symptoms including profound tiredness, musculoskeletal pain, sleep disturbances, and gastrointestinal and neurological problems, along with other CFS symptoms and fibromyalgia (342,346,369).

    Mercury has been found to be a common cause of fibromyalgia(293,346, 369,523,527). Glutamate is the most abundant amino acid in the body, and in the CNS acts as an excitatory neurotransmitter (346,386), which also causes inflow of calcium. Astrocytes, a type of cell in the brain and CNS with the task of keeping clean the area around nerve cells and facilitating neurotransmission, have a function of neutralizing excess glutamate by transforming it to glutamic acid. If astrocytes are not able to rapidly neutralize excess glutamate, then a buildup of glutamate and calcium occurs, causing swelling and neurotoxic effects (119,333). Mercury and other toxic metals inhibit astrocyte function in the brain and CNS(119), causing increased glutamate and calcium related neurotoxicity(119,333,226), which are responsible for many of the fibromyalgia symptoms. This is also a factor in conditions such as CFS, Parkinson's, and ALS(346,416).

    Animal studies have confirmed that increased levels of glutamate (or aspartate, another amino acid excitatory neurotransmitter), cause increased sensitivity to pain , as well as higher body temperature - both found in CFS/fibromyalgia. Mercury and increased glutamate activate free radical forming processes like xanthine oxidase which produce oxygen radicals and oxidative neurological damage(142,346,13). Medical studies and doctors treating fibromyalgia have found that supplements which cause a decrease in glutamate, or protect against its effects, have a positive effect on fibromyalgia. Some that have been found to be effective include vitamin B6, methylcobalamin(B12), L-carnitine, choline, ginseng, Ginkgo biloba, vitamins C and E, nicotine, and omega 3 fatty acids (fish and flaxseed oil-GLA,EPA,DHA)(417,229).

    Other supplements that also have been found to help are magnesium and malic acid(488,489). Avoidance of excitotoxins like MSG and aspartame have been found to eliminate symptoms in some with fibromyalgia(490).

    Clinical tests of patients with chronic neurological conditions, Lupus(SLE), and rheumatoid arthritis, have found that the patients generally have elevated plasma cysteine to sulphate ratios, with the average being 500%higher than controls (330,331,500,33e), and in general being poor sulphur oxidizers. This means that these patients have insufficient sulfates available to carry out necessary bodily processes.

    Mercury has been shown to diminish and block sulphur oxidation, and thus reducing glutathione levels, which is the part of this process involved in detoxifying and excretion of toxics like mercury(33). Glutathione is produced through the sulphur oxidation side of this process. Low levels of available glutathione have been shown to increase mercury retention and increase toxic effects(111), while high levels of free cysteine have been demonstrated to make toxicity due to inorganic mercury more severe(333,194,33e). Mercury has also been found to play a part in inducing intolerance and neuronal problems through blockage of the P-450 liver enzymatic process(84,33e).

    Mercury from amalgam interferes with production of cytokines that activate macrophage and neutraphils, disabling early control of viruses and leading to enhanced infection(131,251). Animal studies have confirmed that mercury increases effects of the herpes simplex virus type 2 for example(131).

    Mercury damages the immune system, and in those with chronic conditions, has been found to commonly facilitate infestation by pathogens such as viruses, harmful bacteria, mycoplasma, candida, and parasites(131,251,404,460,470, 473,485). The majority of those tested who have CFS or fibromyalgia have been found to have infections of mycoplasma, Human Herpes Virus-6, Cytomegalovirus, or bacterial infections such as intracellular chlamydia(470).

    Clinics treating these conditions commonly find such pathogens to be a factor in the condition(470,473,485,487,488). Mercury detoxification and treatment of these pathogens results in significant improvement in the majority of those treated (470,485,488,489,500).

    It has been well documented by hundreds of medical studies including thousands of tested subjects, and by scientific panels, that "amalgam fillings" are the number one source of mercury in people, and that those with several amalgam fillings often have daily exposures exceeding the Government Health Standards for mercury(500).

    Thus, among those most susceptible, significant neurological and immune effects related to amalgam fillings are common. Symptoms of those with CFS, fibromyalgia, or thyroid related conditions, usually improve significantly after proper amalgam replacement.

    In thousands of cases undergoing amalgam replacement, the majority recovered or had significant improvement in symptoms for muscular/joint pain/fibromyalgia (222,293,317,322,369,440,469,470,523,527, 94), Chronic Fatigue Syndrome(8,60,212,293,229,222, 232,233,271,313,317,320,342,369, 375,376,382,440,469,470,485), lupus(113,222, 229,233,323), autoimmune thyroiditis(382), as well as many other conditions(500).

    Of one group of 86 patients with CFS symptoms, 78% reported significant health improvements after replacement of amalgam fillings within a relatively short period, and the MELISA immune reactivity test found significant reduction in lymphocute reactivity compared to pre removal tests(342,375).

    The improvement in symptoms and lymphocute reactivity imply that most of the Hg-induced lymphocute reactivity is allergenic in nature. Although patch tests for mercury allergy are often given for unresolved oral symptoms, this is not generally recommended as a high percentage of such problems are resolved irrespective of the outcome of a patch test (87,90,etc.) Exposure to organochlorine compounds such as DDT/DDE and hexachlorobenzene have also been found to be highly correlated with Chronic Fatigue Syndrome.

    References

    (13) S.Hussain et al, "Mercuric chloride-induced reactive oxygen species and its effect on antioxidant enzymes in different regions of rat brain", Environ Sci Health B 1997 ; 32(3):395-409; & S.Tan et al, "Oxidative stress induces programmed cell death in neuronal cells", J Neurochem, 1998, 71(1):95-105. & J.S. Bains et al, "Neurodegenerative disorders in humans and role of glutathione in oxidative stress mediated neuronal death", Brain Res Rev, 199, 25

    (3):335-58; & P.Bulat, "Activity of Gpx and SOD in workers occupationally exposed to mercury", Arch Occup Environ Health, 1998, Sept, 71 Suppl:S37-9; & Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med 1995; 18(2): 321-36.

    (33)S.C. Langley-Evans et al, "SO2: a potent glutathione depleting agent", Comp Biochem Physiol Pharmacol Toxicol Endocrinol, 114(2):89-98; & (b)P.E. Emory et al, "Increased Prevalence of poor sulphuoxidation in patients with Rheumatoid Arthritis", Ann Rheum Dis, 1992, 51(3): 318-20; & (c) Markovich et al, "Heavy metals (Hg,Cd) inhibit the activity of the liver and kidney sulfate transporter Sat-1", Toxicol Appl Pharmacol, 1999,154(2):181-7; & (d)S.A.McFadden, "Xenobiotic metabolism and adverse environmental response: sulfur-dependent detox pathways", Toxicology, 1996, 111(1-3):43-65.

    (43) Knapp LT; Klann E. Superoxide-induced stimulation of protein kinase C via thiol modification and modulation of zinc content. J Biol Chem 2000 May 22; & B.Rajanna et al, "Modulation of protein kinase C by heavy metals", Toxicol Lett, 1995, 81(2-3):197-203: & A.Badou et al, "HgCl2-induced IL-4 gene expression in T cells involves a protein kinase C-dependent calcium influx through L-type calcium channels", & D.B.Veprintsev, 1996, Institute for Biological Instrumentation, Russian Academy of Sciences, Pb2+ and Hg2+ binding to alpha-lactalbumin". Biochem Mol Biol Int 1996 Aug;39(6):1255-65 (60)V.D.M.Stejskal, Dept. Of Clinical Chemistry, Karolinska Institute, Stockholm, Sweden LYMPHOCYTE IMMUNO-STIMULATION ASSAY -MELISA" & VDM Stejskal et al, "MELISA: tool for the study of metal allergy", Toxicology in Vitro, 8(5):991-1000, 1994. http://www.melisa.org

    (87)A. Skoglund, Scand J Dent Res 102(4): 216-222, 1994; and 99(4):320-9,1991(40 cases); & P.O.Ostman et al, "Clinical & histologic changes after removal of amalgma", Oral Surgery, Oral Medicine, and Endodontics, 1996, 81(4):459-465; & S.H.Ibbotson et al, "The relevance of amalgam replacement on oral lichenoid reactions", British Journal of Dermatology, 134(3):420-3, 1996; & J.Bratel et al, "Effect of Replacement of Dental Amalgam on OLR", Journal of Dentistry, 1996, 24(1-2):41-45(. (431 cases)

    (90)P.Koch et al, "Oral lesions and symptoms related to metals", Dermatol,1999,41(3):422-430; & "Oral lichenoid lesions, mercury hypersensitivity, ...", Contact Dermatitis, 1995, 33(5): 323-328; & S.Freeman et al, "Orallichenoid lesions caused by allergy to mercury in amalgam", Contact Dermatitis, 33(6):423-7, Dec 1995 (Denmark)

    (111)T.W.Clarkson et al, "Billiary secretion of glutathione-metal complexes", Fundam Appl Toxicol, 1985, 5(5):816-31; & D.Quig, Doctors Data Lab,"Cysteine metabolism and metal toxicity", Altern Med Rev, 1998;3:4, p262-270, & J.de Ceaurriz et al, Role of gamma- glutamyltraspeptidase(GGC) and extracellular glutathione in disopition of inorganic mercury",J Appl Toxicol,1994, 14(3): 201-; & W.O. Berndt et al, "Renal glutathione and mercury uptake", Fundam Appl Toxicol, 1985, 5(5):832-9; & R.K. Zulups et al, J Toxicol Environ Health, 1995, 44(4): 385-99; D.Jay, "Glutathione inhibits SOD activity of Hg", Arch Inst cardiol Mex, 1998,68(6):457-61.

    (113)T.A.Glavinskiaia et al, "Complexons in the treatment of lupus erghematousus", Dermatol Venerol, 1980,12: 24-28; & A.F.Hall, Arch Dermatol 47, 1943, 610-611.

    (118) Tibbling L, Stejskal VDM, et al, Immunological and brain MRI changes in patients with suspected metal intoxication", Int J Occup Med Toxicol 4(2):285-294,1995.

    (119) L.Ronnback et al, "Chronic encephalopaties induced by low doses of mercury or lead", Br J Ind Med 49:233-240, 1992; & H.Langauer-Lewowicka," Changes in the nervous system due to occupational metallic mercury poisoning" Neurol Neurochir Pol 1997 Sep-Oct;31(5):905-13; & Kim P, Choi BH. "Selective inhibition of glutamate uptake by mercury in cultured mouse astrocytes", Yonsei Med J 1995; 36(3): 299-305; & Brookes N. In vitro evidence for the role of glutamate in the CNS toxicity of mercury. Toxicology 1992, 76(3):245-56.

    (142)Ariza ME; Bijur GN; Williams MV. Lead and mercury mutagenesis: role of H2O2, superoxide dismutase, and xanthine oxidase. Environ Mol Mutagen 1998;31(4):352-61

    (181)P.W. Mathieson, "Mercury: god of TH2 cells",1995, Clinical Exp Immunol.,102(2):229-30;& & Heo Y, Parsons PJ, Lawrence DA, Lead differentially modifies cytokine production in vitro and in vivo. Toxicol Appl Pharmacol, 196; 138:149-57; & Murdoch RD, Pepys J; Enhancement of antibody and IgE production by mercury and platinum salts. Int Arch Allergy Appl Immunol 1986 80: 405-11.

    (194) Lu SC, FASEB J, 1999, 13(10):1169-83, "Regulation of hepatic glutathione synthesis: current concepts and controversies"; & R.B. Parsons, J Hepatol, 1998, 29(4):595-602; & R.K.Zalups et al,"Nephrotoxicity of inorganic mercury co-administered with L-cysteine", Toxicology, 1996, 109(1): 15-29. & T.L. Perry et al, "Hallevorden-Spatz Disease: cysteine accumulation and cysteine dioxygenase deficiency", Ann Neural, 1985, 18(4):482-489.

    (212)Ziff, M.F., "Documented Clinical Side Effects to Dental Amalgams", ADV. Dent. Res.,1992; 1(6):131-134; & S.Ziff,Dentistry without Mercury, 8th Edition, 1996, Bio-Probe, Inc., ISBN 0-941011-04-6; & Dental Mercury Detox, Bio-Probe, Inc. http://www.bioprobe.com. (cases:FDA Patient Adverse Reaction Reports-762, Dr.M.Hanson-Swedish patients-519, Dr. H. Lichtenberg-100 Danish patients,Dr. P.Larose- 80 Canadian patients, Dr. R.Siblerud, 86 Colorado patients,Dr. A.V.Zamm, 22 patients)

    (222) M. Daunderer, Handbuch der Amalgamvergiftung, Ecomed Verlag, Landsberg 1998, ISBN 3-609-71750-5 (in German); & "Improvement of Nerve and Immunological Damages after Amalgam Removal", Amer. J. Of Probiotic Dentistry and Medicine, Jan 1991;

    (225)S. Yannai et al, "Transformations of inorganic mercury by candida albicans and saccharomyces cerevisiae", Applied Envir Microbiology,1991, 7:245-247; & N.E.Zorn et al, " A relationship between Vit B-12, mercury uptake, and methylation", Life Sci, 1990, 47(2):167-73; & W.P.Ridley et al, Environ Health Perspectives, 1977, Aug 19, 43-6; & R.E.DeSimone et al, Biochem Biophys Acta, 1973,May 28; & Yamada, Tonomura "Formation of methyl Mercury Compounds from inorganic Mercury by Chlostridium cochlearium" J Ferment Technol1972 50:159-1660

    (226) B.J. Shenker et al, Dept. Of Pathology,Univ. Of Penn. School of Dental Med.,"Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes: Alterations in cell viability" Immunopharmacological Immunotoxical, 1992, 14(3):555-77; & M.A.Miller et al, "Mercuric chloride induces apoptosis in human T lymphocytes", Toxicol Appl Pharmacol, 153(2):250-7 1998;& Rossi AD,Viviani B, Vahter M. Inorganic mercury modifies Ca2+ signals, triggers apoptosis, and potentiates NMDA toxicity in cerebral granule neurons. Cell Death and Differentiation 1997; 4(4):317-24. & Goering PL, Thomas D, Rojko JL, Lucas AD. Mercuric chloride-induced apoptosis is dependent on protein synthesis. Toxicol Lett 1999; 105(3): 183-95;

    (234) P.E. Bigazzi, "Autoimmunity and Heavy Metals", Lupus, 1994; 3: 449-453; & Pollard KM, Pearson Dl, Hultman P. Lupus-prone mice as model to study xenobiotic-induced autoimmunity. Environ Health Perspect 1999; 107(Suppl 5): 729-735.

    (235) H.J.Hamre, Mercury from Dental Amalga and Chronic Fatigue Syndrom", The CFIDS Chronicle, Fall 1994, p44-47.

    (265)K.Lohmann et al, "Multiple Chemical Sensitivity Disorder in patients with neurotoxic illnesses", Gesundheitswesen, 1996, 58(6):322-31. (268)J.J.Weening et al, "mercury induced immune complex glomerulopathy", Chap 4, p36-66, VanDendergen, 1980, & P.Duuet et al, "Glomerulonephritis induced by heavy metals", Arch Toxicol. 50:187-194,1982 & Transplantation Proceedings,Vol XIV(3),1982,482-

    (269)(a)C.J.G.Robinson et al, "Mercuric chloride induced antinuclear antibodies In mice", Toxic Appl Pharmacology, 1986, 86:159-169. &(b) P.Andres, IgA-IgG disease in the intestines of rats ingesting HgCl", Clin Immun Immunopath, 30:488-494, 1984; &(c) F.Hirsch et al, J Immun.,136(9), 3272-3276, 1986 & (d)J.Immun.,136(9):3277-3281; & (e)J Immun., 137(8),1986,2548- & (f)Cossi et al, "Beneficial effect of human therapeutic IV-Ig in mercury induced autoimmune disease" Clin Exp Immunol, Apr, 1991; & (g)El-Fawai HA, Waterman SJ, De Feo A, Shamy MY. Neuroimmunotoxicology: Humoral Assessment of Neurotoxicity and Autoimmune Mechanisms. Contact Dermatitis 1999; 41(1): 60-1.

    (270)D.W.Eggleston, "Effect of dental amalgam and nickel alloys on T-lympocytes",J Prosthet Dent. 51(5):617-623, 1984; & D.W.Eggleston et al, J Prosthet Dent, 1987,58(6),704-7; & J of the American Medical Assoc., Sept 96. (288)Rajanna B, Hobson M, Harris L, Ware L, Chetty CS. Effects of cadmium and mercury on Na(+)-K(+)ATPase and uptake of 3H-dopamine in rat brain synaptosomes. Arch Int Physiol Biochem 1990, 98(5):291-6; & M.Hobson & B.Rajanna, "Influence of mercury on uptake of dopamine and norepinephrine", Toxicol Letters, Dep 1985, 27:2-3:7-14; & McKay SJ, Reynolds JN, Racz WJ. Effects of mercury compounds on the spontaneous and potassium-evoked release of [3H]dopamine from mouse striatial slices. Can J Physiol Pharmacol 1986, 64(12):1507-14; & Scheuhammer AM; Cherian MG. Effects of heavy metal cations, sulfhydryl reagents and other chemical agents on striatal D2 dopamine receptors. Biochem Pharmacol 1985 Oct 1;34(19):3405-13 ; Lewis RN; Bowler K. Rat brain (Na+-K+)ATPase: modulation of its ouabain-sensitive K+-PNPPase activity by thimerosal. Int J Biochem 1983;15(1):5-7; & Anner BM, Moosmayer M. Mercury inhibits Na-K-ATPase primarily at the cytoplasmic side. Am J Physiol 1992; 262(5 Pt2):F84308.

    (293)H.Huggins,Burton Goldberg, & Editors of Alternative Medicine Digest,Chronic Fatigue Fibromyalgia & Environmental Illness, Future Medicine Publishing, Inc, 1998, p197.

    (313) V.D.M.Stejskal et al, "Mercury-specific Lymphocytes: an indication of mercury allergy in man", J. Of Clinical Immunology, 1996, Vol 16(1);31-40.

    (314) M.Goldman et al,1991,"Chemically induced autoimmunity ...",Immunology Today,12:223-; & K. Warfyinge et al, "Systemic autoimmunity due to mercury vapor exposure in genetically susceptible mice", Toxicol Appl Pharmacol, 1995, 132(2):299-309;& L.M. Bagentose et al, "Mercury induced autoimmunity in humans", Immunol Res, 1999,20(1): 67-78; &"Mercury-induced autoimmunity", Clin Exp Immunol, 1998, 114(1):9-12.

    (316) B.J.Shenker et al, Dept. Of Pathology, Univ. Of Pennsylvania School of Dental Medicine, "Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes: Alterations in B-cell function and viability" Immunopharmacol Immunotoxicol, 1993, 15(1):87-112;

    (323) Dr. Kohdera, Faculty of Dentistry, Osaka Univ, International Congress of Allergology and Clinical Immunology, EAACI, Stockholm, June 1994; & Heavy Metal Bulletin, Vol 1, Issue 2, Oct 1994. (160 cases cured-eczema,etc.); Tsunetoshi Kohdera, MD, dermatology, allergology, 31 Higashitakada-cho Mibu Nakagyo-ku Schimazu Clinics Kyoto 604 Japan e-mail:smc-inet@mbox.kyoto-inet.or.jp & G. Ionescu, Biol Med, 1996, (2): 65-68; (these clinics use MELISA test for diagnosis of immune reactivity) Neukirchen (clinic)(Germany, near Czech border). Director; Gruia Ionescu, owns 2 Clinics, cases paid by insurance companies in Germany. Email: Spezialklinik-Neukirchen@toolpool.de fax: 0049 9947 10 51 11

    (330) C.M. Tanner et al,"Abnormal Liver Enzyme Metablolism in Parkinson's", Neurology, 1991, 41(5): Suppl 2, 89-92; & M.Watanabe et al, Amino Acids, 1998, 15(2): 143-50 & M.T.Heafield et al, "Plasma cysteine and sulphate levels in patients with Motor neurone disease, Parkinson's Disease, and Alzheimer's Disease", Neurosci Lett, 1990, 110(1-2), 216,20; & A.Pean et al, "Pathways of cysteine metabolism in MND/ALS", J neurol Sci, 1994, 124, Suppl:59-61.

    (331) C.Gordon et al, "Abnormal sulphur oxidation in systemic lupus erythrmatosus(SLE)", Lancet, 1992, 339:8784,25-6; & P.Emory et al, "Poor sulphoxidation in patients with rheumatoid arthritis", Ann Rheum Dis, 1992, 51:3,318-20; & P.Emory et al, Br J Rheumotol, 1992, 31:7,449-51.

    (333) A.J.Freitas et al, "Effects of Hg2+ and CH3Hg+ on Ca2+ fluxes in the rat brain", Brain Research, 1996, 738(2): 257-64; & P.R.Yallapragoda et al,"Inhibition of calcium transport by Hg salts" in rat cerebellum and cerebral cortex", J Appl toxicol, 1996, 164(4): 325-30; & E.Chavez et al, "Mitochondrial calcium release by Hg+2",J Biol Chem, 1988, 263:8, 3582-; A. Szucs et al, Cell Mol Neurobiol, 1997,17(3): 273-8; & D.Busselberg, 1995, "Calcium channels as target sites of heavy metals",Toxicol Lett, Dec;82-83:255-61; & Cell Mol Neurobiol 1994 Dec;14(6):675-87

    (342) V.Stejskal, "MELISA: A New Technology for Diagnosing and Monitoring of Metal Sensitivity", Proceedings: 33rd Annual Meeting of American Academy of Environmental Medicine, Nov. 1998, Baltimore, Maryland; & Stejskal VDM, Danersund A, Lindvall A, Hudecek R, Nordman V, Yaqob A et al. Metal- specific memory lymphoctes: biomarkers of sensitivity in man. Neuroendocrinology Letters, 1999; 20: 289-298.

    (346) Clauw DJ, "The pathogenesis of chronic pain and fatigue syndromes: fibromyalgia" Med Hypothesis, 1995, 44:369-78; & Hanson S, Fibromyalgia, glutamate, and mercury. Heavy Metal Bulletin, Issue 4, 1999, p3-6.

    (348) A Kistner, "Quecksilbervergiftung durch Amalgam: Diagnose und Therapie" ZWR, 1995,104(5):412-417; &(b) Maas C, Bruck W. "Study on the significance of mercury accumulation in the brain from dental amalgam fillings through direct mouth-nose-brain transport", Zentralbl Hyg Umweltmed 1996; 198(3): 275-91; &(c) Villegas J, Martinez R, Andres A, Crespo D. Accumulation of mercury in neurosecretory neurons of mice after long-term exposure to oral mercuric chloride. Neurosci Lett 1999; 271: 93-96; & Kozik MB, Gramza G. Histochemical changes in the neurosecretory hypothalic nuclei as a result of an intoxication with mercury compounds. Acta Histochem Suppl 1980; 22:367-80.

    (368) Olin R, Paulander J, Axelsson P; FMS,CFS, and TMS- Prevalences in a Swedish County, An oral examination based study, Preventive Dental Health Care Center, Karlstad, Sweden, 1998.

    (369) Sterzl I, Prochazkova J, Stejaskal VDM et al, Mercury and nickel allergy: risk factors in fatigue and autoimmunity. Neuroendocrinology Letters 1999; 20:221-228.

    (375) Stejskal VDM, Danersund A, Lindvall A. Metal-specific memory lympocytes: biomarkers of sensitivity in man. Neuroendocrinology Letters 1999.

    (379) MacDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity. The Lancet 1978; Nov 21, 1175-78; & Hickie I, Lloyd A. Are cytokines associated with neuropsychiatric syndrome in humans? Int J Immunopharm 1995; 4:285-294.

    (380) Komaroff AL, Buchwald DS. Chronic fatigue syndrome: an update. Ann Rev Med 1998; 49: 1-13; & Buchwald DS, Wener MH, Kith P. Markers of inflammation and immune activation in CFS. J Rheumatol 1997; 24:372-76.

    (381) Demitrack MA,Dale JK. Evidence for impaired activation of the hypothalamic-pituitary- adrenal axis in patients with chronic fatigue syndrome. J Clin endocrinol Metabol 1991; 73:1224- 1234; & Turnbull AV, Rivier C. Regulation of the HPA axis by cytokines. Brain Behav Immun 1995; 20:253-75.

    (382) Sterzl I, Fucikova T, Zamrazil V. The fatigue syndrome in autoimmune thyroiditis with Polyglanular activation of autoimmunity. Vnitrni Lekarstvi 1998; 44: 456-60; & Sterzl I, Hrda P, Prochazkova J, Bartova J, Reactions to metals in patients with chronic fatigue and autoimmune endocrinopathy. Vnitr Lek 1999 Sep;45(9):527-31

    (383) Saito K. Analysis of a genetic factor of metal allergy-polymorphism of HLA-DR-DO gene. Kokubyo Gakkai Zasschi 1996; 63: 53-69; & Prochazkova J, Ivaskova E, Bartova J, Stejskal VDM. Immunogentic findings in patients with altered tolerance to heavy metals. Eur J Human Genet 1998; 6: 175.

    (385) Kohdera T, Koh N, Koh R. Antigen-specific lympocyte stimulation test on patients with psoriasis vulgaris. XVI International Congress of Allergology and Clinical Immunology, Oct 1997, Cancoon, Mexico; & Ionescu G. Schwermetallbelastung bei atopischer Dermatitis und Psoriasis. Biol Med 1996; 2:65-68.

    (386) Biospectron Lab ....... & Doctors Data Lab ,http://www.doctorsdata.com , inquiries @doctors data.com, & Great Smokies Diagnostic Lab, http://www.gsdl.com; & MetaMatrix Lab, http://www.metamatrix.com

    (404) M. E. Godfrey, Candida, Dysbiosis and Amalgam. J. Adv. Med. vol 9 no 2 (1996).

    (405) Jenny Stejskal, Vera Stejskal. The role of metals in autoimmune diseases and the link to Neuroendocrinology Letters, 20:345-358, 1999.

    (416) Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in ALS. New Engl J Med 1992, 326: 1464-8.

    (417) Folkers K et al, Biochemical evidence for a deficiency of vitamin B6 in subjects reacting to MSL-Glutamate. Biochem Biophys Res Comm 1981, 100: 972; & Felipo V et al, L- carnatine increases the affinity of glutamate for quisqualate receptors and prevents glutamate neurotoxicity. Neurochemical Research 1994, 19(3): 373-377; & Akaike A et al, Protective effects of a vitamin-B12 analog(methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. European J of Pharmacology 1993, 241(1):1-6.

    (440) Kidd RF. Results of dental amalgam removal and mercury detoxification. Altern Ther Health Med 2000 Jul;6(4):49-55.

    (468) Overzet K, Gensler TJ, Kim SJ, Geiger ME, van Venrooij WJ, Pollard KM, Anderson P, Utz PJ. Small nucleolar RNP scleroderma autoantigens associate with phosphorylated serine/arginine splicing factors during apoptosis. Arthritis Rheum 2000 Jun;43(6):1327-36

    (469)BrainRecovery.com, the book, by David Perlmutter MD; Perlmutter Health Center, Naples, Florida, http://www.perlhealth.com/about.htm; & M.M. Van Benschoten and Associates, Reseda, Calif. Clinic; http://www.mmvbs.com

    (470) Dr. Garth Nicholson, Institute for Molecular Medicine, Huntington Beach, Calif., www.immed.org & Michael Guthrie, R.Ph. ImmuneSupport.com 07-18-2001 Mycoplasmas - The Missing Link in Fatiguing Illnesses, www.immunesupport.com/library/showarticle.cfm?ID=3066; & New Treatments for Chronic Infections Found in Fibromyalgia Syndrome, Chronic Fatigue Syndrome, Rheumatoid Arthritis, and Gulf War Illnesses, http://www.immed.org/reports/autoimmune_illness/rep1.html ; & Prof. Garth L. Nicolson, Chronic Fatigue Syndrome, Fibromyalgia Syndrome and Other Fatigue Conditions, http://www.immed.org/illness/fatigue_illness_research.html

    (471) Schwartz RB, Garada BM, Komaroff AL, Gleit M, Holman BL. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MRI and SPECT. Am J Roentgenol, 1994, 162(4):935-41; & Spect Imaging: comparison of findings in patients with CFS, AIDA dementia complex, and major unipolar depression, Am J Roentgenol 1994, 162(4): 943-51; & Ichiso M, Salit IE, Abbey SE. Assessment of regional cerebral perfusion by SPECT in CFS. Nucl Med Commun 1992; 13:767-72.

    (472) Patarca-Monero R, Klimas NG, Fletcher MA. Immunotherapy of chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome. 2001, 8(1): 3-37; & DeBecker P, De Meirleir K, Joos E, Velkeniers B. DHEA response to I.V. ACTH in patients with CFS. Horm Metab Res 1999, 31(1): 18-21.

    (473) De Meirleir K, Bisbal C, Campine I, De Becker, et al. A 37 kDa 1-5A binding proein as a potential biochemical marker for CFS. Am J Med 2000, 108(2): 99-105; & Suhadolnik RJ, Peterson DL, Obrien K, et al, Biochemical evidence for a novel low molecular weight 2-5A-dependent Rnase L in CFS. J Interferon Cytokine Res, 1997, 17(7): 377-85; & Chaudhuri A, Watson WS, Pearn J, Behan PO. The symptoms of chronic fatigue syndrome are related to abnormal ion channel function. Med Hypotheses 2000 Jan;54(1):59-63

    (474) Richards SCM, Bell J, Cheung, YL, Cleare A, Scott DL. Muscle metabolites detected in urine in FM and CFS suggest ongoing muscle damage. Conference Proceedings of the British Society of Rheumatologists, April 2001, Scotland, Abstract 382; http://freespace,virgin.net/david.axford/me_nb_o4.htm.

    (485) Hulda Clark, The Cure for all Diseases, 2000, www.drclark.net.

    (487) Straus SE et al, CFS and allergy, J Allergy Clin Immunol, 1988, 81(5): 791-95; Straus SE et al, Evidence of Epstein-Barr virus infection in CFS, Annals of Internal Med, 1985, 102(1): 7-16; & Jones JF et al, Annals of Internal Med, Evidence for active Epstein-Barr Virus in patients with chronic unexplained illness, 1985, Annals of Internal Med, 102(1): 1-6; & Tyler AN, Influenza A virus: factor in fibromyalgia?, 1997, 2(2): 82- 86.

    (488) Teitelbaum J, Bird B; Effective treatment of CFS, report on 64 patients, J Musculoskeletal Pain, 1995, 3(4): 91-100.

    (489) Behan PO et al; Effect of high doses of essential fatty acids on postviral fatigue syndrome, Acta Neurol Scand, 1990, 82: 209-216; & Abraham GE, Flechas JD; Rationale for the use of magnesium and malic acid in fibromyalgia treatment, Journal of Nutritional Medicine, 1992, 3:40-52.

    (490) Smith JD, Terpening CM, Schmidt SO, Gums JG. Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 2001 Jun;35(6):702-6.

    (500) B. Windham, Common exposure levels from amalgam fillings and related health effects and results of replacement of amalgam fillings on chronic conditions: approx. 60,000 clinical cases followed by doctors. 2001 . (over 1000 medical study references).

    (502) Vielhaber S, Kaufmann J, Kunz WS. Effect of Creatine Supplementation on Metabolite Levels in ALS Motor Cortices. Exp Neurol 2001 Dec;172(2):377-82.

    (518) Landay AL, Jessop C, Lenette ET, chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991; 338:707-12; & Caliguri M, Murray C, Buchwald D. Phenotypic and functional deficiency of natural killer cells in patients with CFS. J Immunol 1987; 139:3306-13; & Barker E, Fujirmura SF, Fadern MB. Immunologic abnormalities associated with CFS. Clin Infect Dis 1994; 18: 136-41.

    (523) CBS Television Network," 60 Minutes", television program narrated by Morley Safer, December 12, 1990

    (527) Cline Medical Center, Vancouver Island, http://www.oceansidemedicine.com/Default.htm